Analyst Ratings for [ARVN] Arvinas Holding Company, LLC

3/13/25	Downgrades	Buy Neutral	X
ARVN Arvinas Goldman
$70 $15
3/12/25	Downgrades	Outperform Neutral	X
ARVN Arvinas Wedbush
$57 $12
3/11/25	Downgrades	Outperform Perform	X
ARVN Arvinas Oppenheimer
12/10/24	Initiated	Buy	X
ARVN Arvinas BTIG Research
$69
11/18/24	Initiated	Overweight	X
ARVN Arvinas Stephens
$55
2/28/24	Reiterated	Outperform	X
ARVN Arvinas Oppenheimer
$95 $80
2/14/24	Downgrades	Buy Neutral	X
ARVN Arvinas Citigroup
$36 $55
12/19/23	Upgrades	Eq Weight Overweight	X
ARVN Arvinas Wells Fargo
$25 $63
12/6/23	Upgrades	Hold Buy	X
ARVN Arvinas Jefferies
$40
11/20/23	Upgrades	Neutral Buy	X
ARVN Arvinas Guggenheim
10/23/23	Upgrades	Neutral Outperform	X
ARVN Arvinas Wedbush
$27 $24
6/26/23	Resumed	Outperform	X
ARVN Arvinas Oppenheimer
$95
1/12/23	Downgrades	Buy Neutral	X
ARVN Arvinas Guggenheim
1/3/23	Downgrades	Overweight Eq Weight	X
ARVN Arvinas Wells Fargo
$83 $49
9/9/22	Initiated	Overweight	X
ARVN Arvinas Barclays
$90
6/21/22	Initiated	Hold	X
ARVN Arvinas Jefferies
$42
5/9/22	Downgrades	Outperform Neutral	X
ARVN Arvinas Wedbush
4/28/22	Initiated	Outperform	X
ARVN Arvinas Credit Suisse
$104
2/11/22	Resumed	Outperform	X
ARVN Arvinas BMO Capital Markets
$125
2/10/22	Initiated	Overweight	X
ARVN Arvinas Wells Fargo
$98
1/19/22	Initiated	Buy	X
ARVN Arvinas Goldman
$157
12/7/21	Initiated	Outperform	X
ARVN Arvinas Cowen
10/14/21	Initiated	Outperform	X
ARVN Arvinas SVB Leerink
$115
5/21/21	Initiated	Buy	X
ARVN Arvinas UBS
$123
4/21/21	Initiated	Buy	X
ARVN Arvinas Truist
$150
3/31/21	Initiated	Outperform	X
ARVN Arvinas BMO Capital Markets
$101
8/6/19	Initiated	Overweight	X
ARVN Arvinas Cantor Fitzgerald
$42
6/5/19	Downgrades	Buy Neutral	X
ARVN Arvinas Citigroup
$21 $22
4/12/19	Initiated	Outperform	X
ARVN Arvinas Evercore ISI
10/22/18	Initiated	Buy	X
ARVN Arvinas Citigroup
$21
10/22/18	Initiated	Neutral	X
ARVN Arvinas Goldman
$17
10/22/18	Initiated	Overweight	X
ARVN Arvinas Piper Jaffray
$23

ARVN Arvinas Holding Company, LLC

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Arvinas Holding Company, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut.